

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response...	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Baskies Arnold M (Last) (First) (Middle) 3150 ALMADEN EXPRESSWAY, SUITE 250 (Street) SAN JOSE, CA 95118 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/27/2018	3. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy) (1)	12/31/2016	09/22/2022	Common Stock	6,000	\$ 0.67	D	
Employee Stock Option (Right to Buy) (1)	09/22/2017	09/22/2022	Common Stock	12,000	\$ 0.67	D	
Employee Stock Option (Right to Buy) (1)	(2)	09/06/2027	Common Stock	20,000	\$ 0.67	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Baskies Arnold M 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE, CA 95118	X			

Signatures

/s/ Arnold M. Baskies		10/01/2018
<small>**Signature of Reporting Person</small>		<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Right to Buy pursuant to the Anixa Biosciences 2010 Share Incentive Plan.

The options vest and become exercisable as follows: a) 10,000 shares shall be vested and exercisable upon grant; b) 8,888 shares shall vest and become exercisable in eight (8) consecutive quarterly installments of 1,111 shares each on the last day of each fiscal quarter, beginning November 30, 2018 and continuing through August 31, 2019; and c) the remaining 1,112 shares shall vest and become exercisable on November 30, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.